BioClinica bites back at Nicusa Capital's call for leadership changes

By Alexandria Pešić and Claire Videau

- Last updated on GMT

Related tags: Management

BioClinica bites back at Nicusa Capital's call for leadership changes
Mark Weinstein, CEO of Bioclinica, has hit back at a public letter from Nicusa Capital CEO, Paul Johnson, claiming that the company's corporate strategy is 'flawed' and demanding the resignation of three top executives.

In an exclusive interview with Outsourcing Pharma, Mr Weinstein explains why he believes he and his collegues were singled out for criticism, and sheds some light on where the battle lines have been drawn in the ongoing dispute.

Related news

Show more

Related products

show more

How a Clinical MDR Helps with Data Quality

How a Clinical MDR Helps with Data Quality

Formedix | 16-Jan-2023 | Technical / White Paper

This article covers the many ways a clinical metadata repository helps with data quality in the clinical trial process, and how it ultimately helps to...

Optimizing Adherence in DCTs

Optimizing Adherence in DCTs

PPD - Decentralized Clinical Trials | 12-Jan-2023 | Technical / White Paper

Prioritizing greater patient-centricity and creating an opportunity to reach unprecedented patient groups, decentralized and hybrid clinical trials are...

PPD is Supporting Complex EU DCTs

PPD is Supporting Complex EU DCTs

PPD - Decentralized Clinical Trials | 05-Jan-2023 | Technical / White Paper

PPD supports European DCTs and clinical trial sponsors with a holistic and comprehensive approach

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 14-Dec-2022 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Related suppliers

Follow us

Products

View more

Webinars